HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 20, No 12, December 2016 – Medical Imaging Technology       » Climate Change Could Hurt Coffee, Help Banana Production       » Partnerships and Innovation: Shaping the Future of Healthcare in Asia Pacific       » Chugai's Novel Antibody Technologies Put Singapore at the Centre of Fight Against Disease       » NUS Scientists Discover the "Switch" that Makes Breast Cancer Cells Aggressive      
EYE in CHINA
A breakthrough in carbohydrate-based vaccine: One vaccine targets three unique glycan epitopes on cancer cells and cancer stem cells
In 2008, the global cancer cases reached 12.7 million, among which 7.6 million people died from cancer. By 2030, the estimated cancer cases may rise to 21.26 million, and the estimated cancer related death may climb to 12.66 million, indicating an overall increase of cancer burden. Currently, the most occurring cancer is lung cancer, followed by breast cancer, colorectal, stomach, prostate and liver cancer, and pancreatic cancer has the highest death rate. According to Health Department of Taiwan, the number one cause of death in Taiwan has been cancer since 1982. In June 21, 2012, a shocking statistics report published by Bureau of Health Promotion stated that 87,189 people were diagnosed to have cancer in 2009, 7,371 more cases than 2008. On average, there was a new cancer case every 6 minutes and 2 seconds in 2009. That's 33 seconds faster than in 2008. The three most occurring types of cancer for men are liver cancer, colon cancer, and lung cancer; the three most occurring types of cancer for women are breast cancer, colon cancer, and lung cancer. For every four men, there is one with cancer, and for women, there is one in every five. The high occurring rate generated a great deal of public concern. People are desperate for a miracle drug to cure cancer. The conventional cancer therapy includes surgery, radiation, chemotherapy, targeted therapy, and antibody therapy. Unfortunately, these treatment regiments are not very effective for late-staged cancer. On the other hand, there has been lack of early diagnosis and no success for the development of cancer vaccine that targets cancer cells, mainly due to lack of unique biomarkers that can be used as targets. Though effective, the cervical cancer vaccine currently on the market targets the virus associated with the cancer but not cancer itself.

Now, a cure for breast cancer may be in sight. The research teams in Genomic Research Center, Academia Sinica have been studying carbohydrate antigens on the surface of cancer cells and cancer stem cells for many years and found some special carbohydrates. Taking account of the vaccine design from the Phase III clinical trial on Globo H-KLH breast cancer immunotherapy in Taiwan, the researchers found that when the hexasaccharide Globo H attached to a diphtheria toxin mutant protein CRM197, DT, in combination with an appropriate adjuvant, such as C34, can efficiently jump-start the immune system and induce abundant IgG antibody to destroy cancer cells. Moreover, the induced antibody specifically recognizes three carbohydrate epitopes, including Globo H, SSEA3 and SSEA4 that only express on breast cancer cells and breast cancer stem cells but not on normal and healthy cells. Compared to the conventional breast cancer target therapy, Herceptin, which is effective for 20% of the breast cancer patients, the Globo H-DT vaccine immunotherapy is expected to be effective for more than 90% of the breast cancer patients and can be developed into a cure or preventive vaccine. These results were recently published in the world renowned Proceedings of the National Academy of Sciences (PNAS) and generated a lot of interest. Dr. Rajendrani Mukhopadhyay, an editorial writer for the American Society for Biochemistry and Molecular Biology (ASBMB), reported this research as a major finding.

Other studies showed that Globo H is found not only on breast cancer, but also on lung, colon, pancreas, endometrium, ovarian, stomach, prostate, and other types of cancer. Therefore, after the vaccine passes the clinical trial and is approved to treat breast cancer, it can be soon apply to treat other eight types of cancer.

Click here for the complete issue.

NEWS CRUNCH  
news Accuron Technologies' MedTech Division Invests into AWAK Technologies
news Philips introduces PerformanceBridge suite of operational performance improvement software and services for radiology departments
news Give a Gift that Will Last a Lifetime this Holiday Season with Smile Train
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Lungs & Respiratory System
February:
Cancer Research, Treatment/Technology
March:
Traditional Chinese Medicines
April:
Eye Care/ Eye Health
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Diabetics Technology
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy